Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Pharmacokinetics of Verzenio (Abemaciclib) in Healthy Subjects
NCT02059148Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abemaciclib in breast cancer (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration at 192 hours, Area Under the Concentration Curve (0-t Last) at 192 hours and 1 more. Started Feb 2014; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02059148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059148.